AKEBIA THERAPEUTICS INC (AKBA) Stock Price, Forecast & Analysis
USA - NASDAQ:AKBA - US00972D1054 - Common Stock
AKBA Key Statistics, Chart & Performance
The current stock price of AKBA is 1.595 USD. In the past month the price decreased by -47.12%. In the past year, price decreased by -12.23%.
AKBA Latest News, Press Relases and Analysis
AKBA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.74 | 412.97B | ||
| AMGN | AMGEN INC | 15.66 | 184.39B | ||
| GILD | GILEAD SCIENCES INC | 15.42 | 156.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 108.46B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.75 | 75.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 901.13 | 60.24B | ||
| INSM | INSMED INC | N/A | 42.56B | ||
| NTRA | NATERA INC | N/A | 29.44B | ||
| BIIB | BIOGEN INC | 9.98 | 24.50B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 21.54B | ||
| INCY | INCYTE CORP | 15.66 | 19.63B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 32.82 | 13.61B |
Related stock screener links
About AKBA
Company Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 181 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. The company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Company Info
AKEBIA THERAPEUTICS INC
245 First Street
Cambridge MASSACHUSETTS 02142 US
CEO: John P. Butler
Employees: 181
Phone: 16178712098
AKEBIA THERAPEUTICS INC / AKBA FAQ
What does AKBA do?
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 181 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. The company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Can you provide the latest stock price for AKEBIA THERAPEUTICS INC?
The current stock price of AKBA is 1.595 USD. The price decreased by -3.33% in the last trading session.
Does AKEBIA THERAPEUTICS INC pay dividends?
AKBA does not pay a dividend.
What is the ChartMill technical and fundamental rating of AKBA stock?
AKBA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting AKBA stock to perform?
11 analysts have analysed AKBA and the average price target is 5.51 USD. This implies a price increase of 245.33% is expected in the next year compared to the current price of 1.595.
Can you provide the growth outlook for AKEBIA THERAPEUTICS INC?
The Revenue of AKEBIA THERAPEUTICS INC (AKBA) is expected to grow by 59.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of AKEBIA THERAPEUTICS INC (AKBA)?
You can find the ownership structure of AKEBIA THERAPEUTICS INC (AKBA) on the Ownership tab.
AKBA Technical Analysis
AKBA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AKBA. While AKBA is still in line with the averages on profitability rating, there are concerns on its financial health.
AKBA Financial Highlights
Over the last trailing twelve months AKBA reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 69.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| Debt/Equity | 4.3 |
AKBA Forecast & Estimates
11 analysts have analysed AKBA and the average price target is 5.51 USD. This implies a price increase of 245.33% is expected in the next year compared to the current price of 1.595.
For the next year, analysts expect an EPS growth of 99.23% and a revenue growth 59.48% for AKBA